
News|Articles|October 28, 2024
Turning obstacles into opportunities: overcoming efficiency and quality challenges in gene therapy development
Author(s)Avantor, Inc.
As the FDA signals stronger support for advancing gene therapy approvals, manufacturers face increasing pressure to get to market quickly while maintaining viral vector quality. This article tackles emerging scale-up challenges to efficiency and safety, with an in-depth look at strategies to optimize viral vector production, manage costs, and collaborate on industry standardization and automation.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Trends in Formulation eBook October 2025
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
4
Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress
5